[go: up one dir, main page]

MX2012000041A - Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta. - Google Patents

Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.

Info

Publication number
MX2012000041A
MX2012000041A MX2012000041A MX2012000041A MX2012000041A MX 2012000041 A MX2012000041 A MX 2012000041A MX 2012000041 A MX2012000041 A MX 2012000041A MX 2012000041 A MX2012000041 A MX 2012000041A MX 2012000041 A MX2012000041 A MX 2012000041A
Authority
MX
Mexico
Prior art keywords
metastatic cancer
predisposed
testing
subject
subject thought
Prior art date
Application number
MX2012000041A
Other languages
English (en)
Other versions
MX341181B (es
Inventor
Pierre Roux
Gilles Gadea
Stephanie Vinot
Christelle Anguille
Jean-Christophe Bourdon
Kenneth Fernandes
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of MX2012000041A publication Critical patent/MX2012000041A/es
Publication of MX341181B publication Critical patent/MX341181B/es

Links

Classifications

    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con un método para someter a prueba a un sujeto que se cree está predispuesto a tener un cáncer metastásico que comprende el paso de i) analizar una muestra biológica de dicho sujeto para detectar la presencia de una isoforma p53 seleccionada en el grupo que consta de 133p53, 133p53y y 133p533, la presencia de dicha isoforma p53 siendo indicativa de un cáncer metastásico.
MX2012000041A 2009-06-30 2010-06-30 Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta. MX341181B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22176909P 2009-06-30 2009-06-30
EP09305633A EP2272979A1 (en) 2009-06-30 2009-06-30 Method for testing a subject thought to be predisposed to having cancer
PCT/EP2010/059321 WO2011000891A1 (en) 2009-06-30 2010-06-30 Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53beta

Publications (2)

Publication Number Publication Date
MX2012000041A true MX2012000041A (es) 2012-04-19
MX341181B MX341181B (es) 2016-08-09

Family

ID=41119348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000041A MX341181B (es) 2009-06-30 2010-06-30 Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.

Country Status (8)

Country Link
US (1) US20120115151A1 (es)
EP (2) EP2272979A1 (es)
JP (1) JP2012531606A (es)
CN (1) CN102471801B (es)
CA (1) CA2766317C (es)
ES (1) ES2601191T3 (es)
MX (1) MX341181B (es)
WO (1) WO2011000891A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014006227A1 (en) * 2012-07-06 2014-01-09 Institut Gustave-Roussy Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
CN102827278B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗肿瘤蛋白p53单克隆抗体及其用途
CN102924594B (zh) * 2012-08-03 2014-05-07 无锡傲锐东源生物科技有限公司 抗肿瘤蛋白p63单克隆抗体及其用途
EP3250679B1 (en) * 2015-01-30 2020-08-19 Centre National de la Recherche Scientifique (CNRS) Reprogramming method for producing induced pluripotent stem cells (ipsc)
EP3250683B1 (en) * 2015-01-30 2020-10-07 Centre National de la Recherche Scientifique (CNRS) Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
DE10234739A1 (de) * 2002-07-30 2004-02-12 Universitätsklinikum Hamburg-Eppendorf Splicing-Variante des humanen p53-Proteins und deren Verwendung zur Herstellung pharmazeutischer Präparate zur Behandlung von Tumorerkrankungen
CN1970763A (zh) * 2006-12-18 2007-05-30 北京市结核病胸部肿瘤研究所 一种截短的抑癌基因p53增加人肺癌细胞对抗肿瘤药物敏感性
WO2009029054A1 (en) * 2007-08-31 2009-03-05 Agency For Science, Technology And Research P53 isoform gene(s) and uses thereof
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
CN102471801B (zh) 2016-05-11
CN102471801A (zh) 2012-05-23
CA2766317C (en) 2019-04-02
ES2601191T8 (es) 2017-06-09
EP2449133A1 (en) 2012-05-09
EP2449133B1 (en) 2016-08-03
EP2272979A1 (en) 2011-01-12
US20120115151A1 (en) 2012-05-10
BRPI1011929A2 (pt) 2016-04-19
WO2011000891A1 (en) 2011-01-06
MX341181B (es) 2016-08-09
CA2766317A1 (en) 2011-01-06
ES2601191T3 (es) 2017-02-14
JP2012531606A (ja) 2012-12-10

Similar Documents

Publication Publication Date Title
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
MX346801B (es) Métodos y composiciones para trastornos relacionados con la proliferación celular.
MX2017003790A (es) Detección de secuencias diana por percepción de nanoporos de sondas sintéticas.
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
ES2570380T3 (es) Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento
BRPI1006595A2 (pt) tira de teste e método para detectar a presença de um análito em uma amostra
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
EA201390638A8 (ru) Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112014025520A2 (pt) método para estimar características de uma formação
BR112012002954A2 (pt) metodo para diagnosticar um disturbio de tireoide, metodo para determinar a capacidade de um composto de induzir um disturbio da tireoide metodo para identificar uma substancia para tratar um disturbio da tireoide, dispositivo para diagnosticar um disturbio da tireoide e uso de pelo menos um analito
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
BRPI1006379A2 (pt) método e analisador de dados
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
AR093172A1 (es) Polimeros quimicamente marcados para la cuantificacion simplificada y metodos relacionados
GB2509682A (en) Biomarkers useful for detection of tyres, grades and stages of human breast cancer
MX2012000041A (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
CL2012001353A1 (es) Método de detección de un evento de soja en una muestra basada en poner en contacto dicha muestra con un polinucleótido específico para el evento aad-12 pdab4468-0416; método para determinar cigocidad de dicho evento en una planta de soja y kit de detección de adn.
BRPI1009460A2 (pt) domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.
BR112014014279A2 (pt) método para obter dados úteis para o diagnóstico e/ou prognóstico de insuficiência renal aguda; uso de pelo menos um micro-rna; kit para o diagnóstico e/ou prognóstico de insuficiência renal aguda e uso do kit

Legal Events

Date Code Title Description
FG Grant or registration